We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program

News   Nov 16, 2009

 
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
 
 
 

RELATED ARTICLES

Experimental Nasal Influenza Vaccine Tested in Kids, Teens

News

NIH-supported Phase 1 trial of potential broadly protective vaccine.

READ MORE

Gout Get Outta Here

News

Researchers found a significant reduction in risk of gout attacks among patients who received the drug (canakinumab) that targets a key inflammatory molecule, suggesting a new target for therapeutic strategies to prevent gout attacks.

READ MORE

Better Tailored Drugs with Fewer Side-Effects

News

A recent achievement in the field of protein research allows for better tailored pharmaceuticals with fewer side-effects.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE